BioGaia’s probiotic found to prevent recurrent diarrhea and promote growth in children

a56e4159-6c57-45b5-bc01-710f73a4865darticleimage.jpg

07 Nov 2017 --- Rapid diagnostic testing and Lactobacillus reuteri Protectis supplementation for 60 days has been linked to a significant increase in height and significantly less recurrent diarrhea in study of 71 infants with acute diarrhea, as compared to standard care and placebo treatment. Lactobacillus reuteri Protectis is a strain developed by Swedish healthcare company BioGaia.

“These results are very exciting. Our trial has shown that the administration of L. reuteri DSM 17938 shows real promise to mitigate the devastating effects of diarrheal disease in sub-Saharan Africa,” says Associate Professor Jeffrey Pernica at McMaster Children’s Hospital in Hamilton, Canada, lead investigator of the study.

“Previous probiotic trials have focused on outcomes such as duration of diarrhea, which are somewhat relevant for families and clinicians, but not nearly as important as a hard outcome such as standardized height, which has been directly linked to stunting, cognitive deficiencies, and eventual adult accomplishment,” Pernica explains. “The combination of test-and-treat diagnostics and L. reuteri DSM 17938 was associated with 93 percent lower odds of recurrent diarrhea in the 60-day follow-up period, as well as a dramatic increase in age-standardized height.”

Diarrhea kills and disables children
Diarrhea is the second-leading cause of mortality in the world among children under the age of 5, as well as a major cause of both growth failure and impaired cognitive development. There is a clear need for improvements in diarrheal disease management in resource-limited settings.

The pilot study was conducted in Botswana and demonstrated that the use of molecular rapid enteric diagnostics (permitting timely targeted antimicrobial therapy) and the administration of L. reuteri Protectis were both feasible in a resource-limited sub-Saharan African context. These interventions led to significant increases in growth and decreases in recurrent diarrhea. The next step will be to validate these findings in a trial with a much larger number of children.

BioGaia first announced the results in October 2015 when the study was presented for the first time at The Infectious Disease Week in San Diego, USA, but the findings were published in PLOS ONE on 9 October.

“We had announced the results of this study already, in October 2015, but now have the opportunity to highlight them again. The fact that L. reuteri Protectis may mitigate terrible consequences of diarrheal disease, like stunting, cognitive deficiencies, and eventual adult accomplishments, and contribute to a decrease in recurrent diarrhea, increased growth and improved quality of life for children in sub-Saharan countries is very encouraging”, says Axel Sjöblad, Managing Director at BioGaia.

Related Articles

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

Nutrition & Health News

DuPont’s Microbiome Venture aims to lead development of new microbiome science-based solutions

30 Nov 2017 --- DuPont Nutrition & Health has announced the development of what it describes as a “significant new initiative” with the creation of its Microbiome Venture to spearhead the development of new microbiome science-based solutions. The Microbiome Venture will play a key role in DuPont’s business growth strategy.

Nutrition & Health News

Modifying gut microbiome may eventually prevent asthma in infant boys

29 Nov 2017 --- The family risk for asthma – typically passed from mothers to babies – may involve the microbes found in a baby's digestive tract. This is according to a new University of Alberta study, funded by the Canadian Institutes of Health Research (CIHR) and AllerGen and published in the European Respiratory Journal.

More Articles
URL : http://www.nutritioninsight.com:80/news/biogaias-probiotic-found-to-prevent-recurrent-diarrhea-and-promote-growth-in-children.html